查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1753989

2025 年至 2033 年乳癌液體活體組織切片市場報告（按產品服務、循環生物標記（循環腫瘤細胞、遊離 DNA、細胞外囊泡等）、最終用戶和地區分類）

Breast Cancer Liquid Biopsy Market Report by Product Services, Circulating Biomarker (Circulating Tumor Cells, Cell-Free DNA, Extracellular Vesicles, and Others), End User, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

2024年，全球乳癌液體切片市場規模達1.507億美元。展望未來， IMARC Group預計到2033年，該市場規模將達到5.534億美元，2025-2033年期間的複合年成長率（CAGR）為14.77%。乳癌盛行率的上升、向非侵入性診斷方法的轉變、技術的持續進步以及癌症研究投入的激增，是推動市場成長的主要因素。

乳癌液體活體組織切片市場分析：

  • 主要市場促進因素：乳癌發生率的不斷上升以及對非侵入性醫療程序日益成長的需求，是推動全球乳癌液體活體組織切片市場需求成長的主要動力。此外，消費者對液體切片技術許多益處的認知不斷提高，包括更快的結果、更低的成本、最小的健康風險、非侵入性等，也促進了市場的成長。
  • 主要市場趨勢：政府和私人機構對乳癌活體組織切片及其他相關醫療程序的報銷政策日益增多，為市場帶來了積極的前景。此外，個人化治療的興起，以及聚合酶鍊式反應 (PCR) 和新一代定序 (NGS) 在癌症檢測中的廣泛應用，將在未來幾年繼續推動全球乳癌液體活體組織切片市場的發展。
  • 競爭格局：一些著名的乳癌液體切片市場公司包括 Biocept Inc.、Bio-Rad Laboratories Inc.、F. Hoffmann-La Roche AG、Fluxion Biosciences Inc.、Guardant Health Inc.、Illumina Inc.、Menarini Silicon Biosystems（The Menarini Group）、NimGenom Corporation Ixjx、Mwash、Aw、k、k（Ssmh）等。
  • 地理趨勢：根據乳癌液體活體組織切片市場預測報告，北美目前佔據整個市場的主導地位。乳癌仍然是北美女性最常見的癌症之一。病例數量的不斷成長刺激了對液體活體組織切片等更有效、侵入性更低的診斷工具的需求。
  • 挑戰與機會：液體活體組織切片的高昂開發和驗證成本以及監管障礙阻礙了市場的成長。然而，液體切片可用於檢測微小殘留病灶 (MRD)，即治療後殘留的少量癌細胞，最終可能導致復發。這項技術為治療後監測帶來了重大機會。

乳癌液體切片市場趨勢：

乳癌發生率不斷上升

全球乳癌盛行率的上升是主要促進因素之一。例如，根據世界衛生組織 (WHO) 的數據，2022 年全球將有近 230 萬名女性被診斷出罹患乳癌，約有 67 萬名女性死亡。同樣，根據美國國家乳癌基金會的數據，在美國，每 8 名女性中就有 1 名在其一生中會被診斷出罹患乳癌。到 2024 年，預計將有 310,720 名女性和 2,800 名男性被診斷出患有侵襲性乳癌。由於乳癌仍然是全球女性中最常見的癌症之一，對液體活體組織切片等早期檢測和監測解決方案的需求正在上升。預計這些因素將在未來幾年推動乳癌液體活體組織切片市場佔有率的成長。

注重早期檢測

乳癌的早期發現可顯著改善患者的預後，而液體活體組織切片比一些傳統的影像方法能夠更早發現。例如，根據美國國家醫學圖書館發表的一篇文章，液體活體組織切片已顯示出在早期診斷癌症、追蹤腫瘤生長和復發以及預測患者治療反應的潛力。它還能實現持續監測，這對於追蹤病情進展和治療反應至關重要，使其成為現代腫瘤學的重要工具。這些因素進一步對乳癌液體活體組織切片市場預測產生了積極影響。

產品創新

基因組定序、分子生物學和生物資訊學領域的創新正在提高液體活體組織切片技術的靈敏度、特異性和準確性。例如，2023年11月，DNA定序和基於陣列的技術公司Illumina Inc.開發了其分散式液體活體組織切片檢測方法的改進版本，用於基因組分析。新的TruSight Oncology 500 ctDNA v2（TSO 500 ctDNA v2）是一種研究檢測方法，可對血液中的循環腫瘤DNA (ctDNA) 進行非侵入性全面基因組分析 (CGP)。這些進步有助於早期癌症檢測、療效監測和抗藥性突變識別，從而推動液體活體組織切片在臨床環境中的應用，從而促進乳癌液體活體組織切片市場的成長。

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

  • 概述
  • 主要行業趨勢

第5章：全球乳癌液體切片市場

  • 市場概覽
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場區隔：依產品服務

  • 試劑盒
  • 儀器
  • 服務

第7章：市場區隔：按循環生物標記

  • 循環腫瘤細胞（CTC）
  • 遊離DNA（cfDNA）
  • 細胞外囊泡（EVs）
  • 其他

第8章：市場區隔：按最終用戶

  • 參考實驗室
  • 醫院和醫生實驗室
  • 其他

第9章：市場細分：依地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場區隔：依國家

第10章：SWOT分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第13章：價格分析

第 14 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Biocept Inc.
    • Bio-Rad Laboratories Inc.
    • F. Hoffmann-La Roche AG
    • Fluxion Biosciences Inc.
    • Guardant Health Inc.
    • Illumina Inc.
    • Menarini Silicon Biosystems (The Menarini Group)
    • NeoGenomics Laboratories Inc.
    • Qiagen
    • Sysmex Europe SE (Sysmex Corporation)
Product Code: SR112025A6047

The global breast cancer liquid biopsy market size reached USD 150.7 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 553.4 Million by 2033, exhibiting a growth rate (CAGR) of 14.77% during 2025-2033. The rising prevalence of breast cancer, shift towards non-invasive diagnostic methods, ongoing technological advancements, and surging investment in cancer research, are primarily driving the market's growth.

Breast Cancer Liquid Biopsy Market Analysis:

  • Major Market Drivers: The growing prevalence of breast cancer along with the escalating demand for non-invasive medical procedures is primarily driving the global breast cancer liquid biopsy market demand. In addition to this, the rising consumer awareness towards numerous benefits associated with the liquid biopsy technique, including quicker results, lower cost, minimal health risk, non-invasiveness, etc., is also augmenting the market growth.
  • Key Market Trends: The increasing number of government and private reimbursement policies for breast cancer biopsy and other related medical procedures is creating a positive outlook for the market. Additionally, the emerging trend of personalized therapeutics coupled with the widespread adoption of polymerase chain reaction (PCR) and next-generation sequencing (NGS) for cancer detection will continue to drive the global breast cancer liquid biopsy market in the coming years.
  • Competitive Landscape: Some of the prominent breast cancer liquid biopsy market companies include Biocept Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, Fluxion Biosciences Inc., Guardant Health Inc., Illumina Inc., Menarini Silicon Biosystems (The Menarini Group), NeoGenomics Laboratories Inc., Qiagen, and Sysmex Europe SE (Sysmex Corporation), among many others.
  • Geographical Trends: According to the breast cancer liquid biopsy market forecast report, North America currently dominates the overall market. Breast cancer remains one of the most common cancers affecting women in North America. The increasing number of cases fuels the demand for more effective and less invasive diagnostic tools like liquid biopsies.
  • Challenges and Opportunities: The high costs of developing and validating liquid biopsy tests and regulatory hurdles are hampering the market's growth. However, liquid biopsies can be used to detect minimal residual disease (MRD), where small amounts of cancer remain after treatment and may eventually cause a recurrence. This capability presents a major opportunity in post-treatment monitoring.

Breast Cancer Liquid Biopsy Market Trends:

Increasing Prevalence of Breast Cancer

The increasing global prevalence of breast cancer is one of the primary drivers. For instance, according to the World Health Organization (WHO), in 2022, nearly 2.3 million women were diagnosed with breast cancer, and approximately 670,000 died worldwide. Similarly, according to the National Breast Cancer Foundation, in the United States, 1 out of every 8 women will be diagnosed with breast cancer during their lifetime. In 2024, an estimated 310,720 women and 2,800 males will be diagnosed with invasive breast cancer. As breast cancer remains one of the most common cancers among women worldwide, the demand for early detection and monitoring solutions, like liquid biopsy, is rising. These factors are expected to propel the breast cancer liquid biopsy market share in the coming years.

Focus on Early Detection

Early detection of breast cancer significantly improves patient outcomes, and liquid biopsy allows for earlier detection than some traditional imaging methods. For instance, according to an article published by the National Library of Medicine, LB has demonstrated potential in diagnosing cancer at an early stage, tracking tumor growth and recurrence, and predicting patient response to therapy. It also enables continuous monitoring, which is essential for tracking disease progression and treatment response, making it an essential tool in modern oncology. These factors further positively influence the breast cancer liquid biopsy market forecast.

Product Innovations

Innovations in genomic sequencing, molecular biology, and bioinformatics are enhancing the sensitivity, specificity, and accuracy of liquid biopsy techniques. For instance, in November 2023, Illumina Inc., a DNA sequencing and array-based technology business, developed an improved version of their distributed liquid biopsy assay for genomic profiling. The new TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) is a research assay that allows for non-invasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) from blood. These advancements help in early cancer detection, monitoring treatment efficacy, and identifying resistance mutations, which drives the adoption of liquid biopsy in clinical settings, thereby boosting the breast cancer liquid biopsy market growth.

Global Breast Cancer Liquid Biopsy Industry Segmentation:

Breakup by Product Services:

  • Reagent Kits
  • Instruments
  • Services

Currently, reagent kits account for the majority of the global market share

According to the breast cancer liquid biopsy market outlook, the increasing global incidence of breast cancer has heightened the need for better diagnostic, monitoring, and screening tools. As liquid biopsy becomes more commonly used, the demand for reagent kits that support these tests rises proportionally. Moreover, traditional tissue biopsies are invasive and can cause discomfort and complications. Liquid biopsy offers a non-invasive alternative, which is gaining popularity for both diagnostic and treatment monitoring purposes. This shift is a key driver for reagent kits used in liquid biopsy procedures, such as those for detecting circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs).

Breakup by Circulating Biomarker:

  • Circulating Tumor Cells (CTCs)
  • Cell-Free DNA (cfDNA)
  • Extracellular Vesicles (EVs)
  • Others

According to the breast cancer liquid biopsy market analysis report, CTCs are cancer cells that have shed from the primary tumor into the bloodstream. The presence of CTCs in the blood correlates with disease stage and prognosis. Higher numbers of CTCs are often associated with advanced cancer and poorer outcomes. Moreover, cfDNA consists of small fragments of DNA released from tumor cells (also referred to as circulating tumor DNA or ctDNA) and other cells into the bloodstream. Moreover, analysis of cfDNA allows for the detection of specific mutations, such as those in the PIK3CA gene, TP53, or ESR1, which can guide treatment choices, especially for targeted therapies. Furthermore, extracellular vesicles (such as exosomes and microvesicles) are small membrane-bound particles released by cells, including cancer cells, into the bloodstream. EVs contain a variety of biomolecules, including proteins, RNA, DNA, and lipids, and can play a role in cell-to-cell communication.

Breakup by End User:

  • Reference Laboratories
  • Hospitals and Physician Laboratories
  • Others

According to the breast cancer liquid biopsy market outlook report, reference labs often have access to the most cutting-edge technologies in liquid biopsy, including next-generation sequencing (NGS) and circulating tumor DNA (ctDNA) analysis. Their advanced infrastructure attracts demand from hospitals and physician labs that do not have these capabilities. Moreover, large hospitals, especially those with dedicated oncology centers, have a high volume of breast cancer patients requiring regular monitoring. Liquid biopsy offers a less invasive, faster alternative to traditional tissue biopsies for diagnosis, treatment monitoring, and recurrence detection. Furthermore, physical labs are often the first point of care for breast cancer screening. Liquid biopsies provide a more accessible and less invasive option for patients at high risk of breast cancer, allowing for earlier detection and intervention.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America currently dominates the global market

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America dominates the global market.

According to the breast cancer liquid biopsy market statistics, breast cancer remains one of the most common cancers among women in North America, driving demand for improved diagnostic tools. Moreover, liquid biopsies offer a non-invasive alternative to traditional tissue biopsies, which can be painful, risky, and difficult to perform, especially in advanced cancer cases. As a simple blood test, liquid biopsy is more appealing to patients, contributing to its growing adoption. Besides this, advances in liquid biopsy technologies, including next-generation sequencing (NGS), PCR-based methods, and improved ctDNA and CTC (circulating tumor cells) detection platforms, have significantly increased the accuracy and sensitivity of these tests. These innovations are driving wider clinical adoption of liquid biopsy for breast cancer diagnosis and monitoring.

Competitive Landscape:

The breast cancer liquid biopsy market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:

  • Biocept Inc.
  • Bio-Rad Laboratories Inc.
  • F. Hoffmann-La Roche AG
  • Fluxion Biosciences Inc.
  • Guardant Health Inc.
  • Illumina Inc.
  • Menarini Silicon Biosystems (The Menarini Group)
  • NeoGenomics Laboratories Inc.
  • Qiagen
  • Sysmex Europe SE (Sysmex Corporation)

Key Questions Answered in This Report

  • 1.What was the size of the global breast cancer liquid biopsy market in 2024?
  • 2.What is the expected growth rate of the global breast cancer liquid biopsy market during 2025-2033?
  • 3.What has been the impact of COVID-19 on the global breast cancer liquid biopsy market?
  • 4.What are the key factors driving the global breast cancer liquid biopsy market?
  • 5.What is the breakup of the global breast cancer liquid biopsy market based on the product services?
  • 6.What are the key regions in the global breast cancer liquid biopsy market?
  • 7.Who are the key players/companies in the global breast cancer liquid biopsy market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Breast Cancer Liquid Biopsy Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Services

  • 6.1 Reagent Kits
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Instruments
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Services
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Circulating Biomarker

  • 7.1 Circulating Tumor Cells (CTCs)
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Cell-Free DNA (cfDNA)
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Extracellular Vesicles (EVs)
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Reference Laboratories
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Hospitals and Physician Laboratories
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Biocept Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Bio-Rad Laboratories Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 F. Hoffmann-La Roche AG
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Fluxion Biosciences Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Guardant Health Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Illumina Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 Menarini Silicon Biosystems (The Menarini Group)
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 NeoGenomics Laboratories Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Qiagen
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Sysmex Europe SE (Sysmex Corporation)
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio

List of Figures

  • Figure 1: Global: Breast Cancer Liquid Biopsy Market: Major Drivers and Challenges
  • Figure 2: Global: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019-2024
  • Figure 3: Global: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 4: Global: Breast Cancer Liquid Biopsy Market: Breakup by Product Services (in %), 2024
  • Figure 5: Global: Breast Cancer Liquid Biopsy Market: Breakup by Circulating Biomarker (in %), 2024
  • Figure 6: Global: Breast Cancer Liquid Biopsy Market: Breakup by End User (in %), 2024
  • Figure 7: Global: Breast Cancer Liquid Biopsy Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Breast Cancer Liquid Biopsy (Reagent Kits) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Breast Cancer Liquid Biopsy (Reagent Kits) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Breast Cancer Liquid Biopsy (Instruments) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Breast Cancer Liquid Biopsy (Instruments) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Breast Cancer Liquid Biopsy (Services) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Breast Cancer Liquid Biopsy (Services) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Breast Cancer Liquid Biopsy (Circulating Tumor Cells (CTCs)) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Breast Cancer Liquid Biopsy (Circulating Tumor Cells (CTCs)) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Breast Cancer Liquid Biopsy (Cell-Free DNA (cfDNA)) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Breast Cancer Liquid Biopsy (Cell-Free DNA (cfDNA)) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Breast Cancer Liquid Biopsy (Extracellular Vesicles (EVs)) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Breast Cancer Liquid Biopsy (Extracellular Vesicles (EVs)) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Breast Cancer Liquid Biopsy (Other Circulating Biomarkers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Breast Cancer Liquid Biopsy (Other Circulating Biomarkers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Breast Cancer Liquid Biopsy (Reference Laboratories) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Breast Cancer Liquid Biopsy (Reference Laboratories) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Breast Cancer Liquid Biopsy (Hospitals and Physician Laboratories) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Breast Cancer Liquid Biopsy (Hospitals and Physician Laboratories) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Breast Cancer Liquid Biopsy (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Breast Cancer Liquid Biopsy (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: North America: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: North America: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: United States: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: United States: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Canada: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Canada: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Asia-Pacific: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Asia-Pacific: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: China: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: China: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Japan: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Japan: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: India: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: India: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: South Korea: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: South Korea: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Australia: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Australia: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Indonesia: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Indonesia: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Others: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Others: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Europe: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Europe: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Germany: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Germany: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: France: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: France: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: United Kingdom: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: United Kingdom: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Italy: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Italy: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Spain: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Spain: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Russia: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Russia: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Others: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Others: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Latin America: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Latin America: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Brazil: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Brazil: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Mexico: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Mexico: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Others: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Others: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Middle East and Africa: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Middle East and Africa: Breast Cancer Liquid Biopsy Market: Breakup by Country (in %), 2024
  • Figure 76: Middle East and Africa: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Global: Breast Cancer Liquid Biopsy Industry: SWOT Analysis
  • Figure 78: Global: Breast Cancer Liquid Biopsy Industry: Value Chain Analysis
  • Figure 79: Global: Breast Cancer Liquid Biopsy Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Breast Cancer Liquid Biopsy Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Breast Cancer Liquid Biopsy Market Forecast: Breakup by Product Services (in Million USD), 2025-2033
  • Table 3: Global: Breast Cancer Liquid Biopsy Market Forecast: Breakup by Circulating Biomarker (in Million USD), 2025-2033
  • Table 4: Global: Breast Cancer Liquid Biopsy Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 5: Global: Breast Cancer Liquid Biopsy Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Breast Cancer Liquid Biopsy Market: Competitive Structure
  • Table 7: Global: Breast Cancer Liquid Biopsy Market: Key Players